Subgroup analyses Annualized relapse rate The significant reduction in ARR observed in the overall pooled analysis of the ITT population with ocrelizumab, relative to IFN β-1a (47% [ p < 0.001]), was maintained across the majority of subgroup-levels, including study, region, age, sex, baseline BMI, prior DMT use and prior relapse, baseline EDSS, normalized brain volume, and gadolinium-enhancing T1 lesions; a numerical trend favoring ocrelizumab was observed for the specific subgroup strata of patients aged ≥ 40 years (Fig. 1 ).
← all excerpts
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
1
—
—